文献速递肺外科

临床IA期NSCLC肺段切除后隐匿性pN1/pN2:是否需补行肺叶切除?

Clinical stage IA non-small cell lung cancer with occult pathologic N1 and N2 disease after segmentectomy: does a completion lobectomy justify?
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

基于美国国家癌症数据库(NCDB)2010–2020年临床IA期NSCLC接受肺段或肺叶切除的患者,比较不同病理N分期的生存与围术期结局。肺段切除后隐匿性pN1在2年内生存优于肺叶切除,2年后相似;pN2生存与肺叶切除相似。肺段切除短期死亡率、再入院率更低、住院更短,完全切除后可能无需补行肺叶切除。

要点

  • 临床IA期NSCLC肺段切除后隐匿性pN1,2年内生存优于肺叶切除。
  • 肺段切除后隐匿性pN2生存与肺叶切除相似。
  • 完全切除的临床IA期患者,pN1/N2发现后可能无需补行肺叶切除。

核心结论

  • 临床IA期NSCLC肺段切除后隐匿性pN1和pN2的生存至少不劣于肺叶切除。
  • 永久病理提示pN1或N2后可能不需要补行肺叶切除。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(NCDB)2010–2020年临床IA期NSCLC接受肺段或肺叶切除的患者。
  • 共纳入123 085例临床IA期NSCLC,其中7.9%接受肺段切除。

主要发现

  • 肺段切除后病理pN1占2.8%、pN2占1.9%;肺叶切除后pN1占6.5%、pN2占3.7%。
  • pN1患者肺段切除2年内生存优于肺叶切除(aHR=0.67,P=0.03),2年后相似(aHR=1.06,P=0.7)。
  • pN2患者肺段切除与肺叶切除生存相似(aHR=0.96,P=0.7)。
  • 全部临床IA期患者中,肺段切除较肺叶切除30天死亡率(aOR=0.55,P<0.001)、90天死亡率(aOR=0.57,P<0.001)、再入院(aOR=0.86,P=0.01)更低,住院更短(aRR=0.76,P<0.001)。

临床怎么用

  • 临床IA期NSCLC肺段切除后若病理为pN1或pN2,可考虑不补行肺叶切除。
  • 肺段切除与更低的短期死亡率、再入院率和更短住院相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: When final pathology shows pathologic N1 or N2 disease after a pulmonary segmentectomy for early stage non-small cell lung cancer (NSCLC), completion of lobectomy could be considered and recommended as an option for treatment. We explored outcomes after segmentectomy for clinical stage IA NSCLC with occult pN1 or pN2 disease. METHODS: We identified clinical stage IA NSCLC undergoing segmentectomy or lobectomy from the National Cancer Database (NCDB) between 2010 and 2020. We categorized patients by pathologic N diseases (pN0/pN1/pN2). We compared segmentectomy to lobectomy adjusting for patient and clinical characteristics. We explored survival using time-varied Cox regression, 30-day, 90-day mortality and unplanned 30-day readmission using logistic regression, and length of stay using Poisson regression. RESULTS: Of 123 085 clinical IA NSCLC, 7.9% underwent segmentectomy. Pathology showed 2.8% pN1 and 1.9% pN2 after segmentectomy, and 6.5% pN1 and 3.7% pN2 after lobectomy. For pN1, segmentectomy conferred 33% better survival within 2 years (aHR = 0.67, P = 0.03), but similar survival after 2 years (aHR = 1.06, P = 0.7). For pN2, segmentectomy had similar survival with lobectomy (aHR = 0.96, P = 0.7). For all clinical IA NSCLC, segmentectomy was associated with lower 30-day mortality (aOR = 0.55, P < 0.001), 90-day mortality (aOR = 0.57, P < 0.001), readmission (aOR = 0.86, P = 0.01) and shorter length of stay (aRR = 0.76, P < 0.001) than lobectomy. CONCLUSIONS: Outcomes after segmentectomy for clinical stage IA NSCLC may be associated with better short-term mortality, readmission rate and length of stay. Survival with occult pN1 and pN2 after segmentectomy is at least equivalent to lobectomy in completely resected clinical stage IA patients. A completion lobectomy may not be needed after pN1 and N2 findings after the permanent pathology was released.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Luo X, Hayanga JWA, Mehaffey JH, et al. Clinical stage IA non-small cell lung cancer with occult pathologic N1 and N2 disease after segmentectomy: does a completion lobectomy justify? Eur J Cardiothorac Surg. 2024. PMID: 39563408. doi:10.1093/ejcts/ezae415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。